Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been assigned a consensus recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $23.00.

AURA has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday, November 14th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st.

Aura Biosciences Trading Down 1.6 %

NASDAQ AURA opened at $7.51 on Thursday. The firm’s fifty day simple moving average is $7.99 and its two-hundred day simple moving average is $8.73. The firm has a market capitalization of $375.12 million, a P/E ratio of -4.34 and a beta of 0.29. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38.

Insider Buying and Selling at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 23,045 shares of company stock worth $177,242 over the last quarter. 5.40% of the stock is currently owned by company insiders.

Institutional Trading of Aura Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AURA. Long Focus Capital Management LLC raised its holdings in shares of Aura Biosciences by 123.9% in the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock valued at $20,861,000 after buying an additional 1,404,228 shares during the period. Vanguard Group Inc. increased its stake in Aura Biosciences by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company’s stock worth $15,764,000 after purchasing an additional 112,296 shares during the period. Franklin Resources Inc. increased its stake in Aura Biosciences by 3.2% during the fourth quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company’s stock worth $14,164,000 after purchasing an additional 54,103 shares during the period. Levin Capital Strategies L.P. increased its stake in Aura Biosciences by 169.1% during the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock worth $10,255,000 after purchasing an additional 783,984 shares during the period. Finally, Geode Capital Management LLC increased its stake in Aura Biosciences by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after purchasing an additional 3,972 shares during the period. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.